SCHEMBL15420558

SCHEMBL15420558

CCS(=O)(=O)N[C@H]1CCOC[C@@H]1COc1ccc(-c2ccc(Cl)cn2)cc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 2/20 0.37
XDH P47989 1/20 0.36
CYP11B2 P19099 2/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
APLNR P35414 2/20 0.32
GPR119 Q8TDV5 2/20 0.32
GPR183 P32249 1/20 0.32
ATF4 P18848 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32
MCHR1 Q99705 2/20 0.32
GRM4 Q14833 1/20 0.32
SMO Q99835 1/20 0.32
ITGA5 P08648 1/20 0.31
GABRA5 P31644 1/20 0.31
DGAT1 O75907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420361 1.00 GRIA2 (0.37) GRIA2XDHCYP11B2NPC1RAB9A
SCHEMBL12987263 1.00 GRIA2 (0.37) GRIA2XDHCYP11B2NPC1RAB9A
SCHEMBL13192658 0.94 GRIA2 (0.36) GRIA2XDHCYP11B2NPC1RAB9A
SCHEMBL12987919 0.93 GRIA2 (0.37) GRIA2XDHCYP11B2NPC1RAB9A
SCHEMBL15420203 0.91 GRIA2 (0.38) GRIA2XDHCYP11B2GPR119GPR183
SCHEMBL12987282 0.91 GRIA2 (0.38) GRIA2XDHCYP11B2GPR119GPR183
SCHEMBL15420333 0.90 CHRNA7 (0.37) GRIA2XDHNPC1RAB9ASMN1; SMN2
SCHEMBL15441176 0.90 CHRNA7 (0.37) GRIA2XDHNPC1RAB9ASMN1; SMN2
SCHEMBL15420521 0.89 NPC1 (0.44) XDHNPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL15441034 0.89 GRIA2 (0.46) GRIA2XDHGPR119GPR183MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 GRIA2 12/4885XDH 499/4885CYP11B2 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.